Chronic Lymphocytic Leukemia | Specialty

Dr. Siddiqi on the Results of the TRANSCEND CLL 004 Trial in CLL

February 11th 2020

Tanya Siddiqi, MD, discusses the results of the TRANSCEND CLL 004 trial.

Dr. Furman on Acalabrutinib Monotherapy in CLL

February 11th 2020

Richard R. Furman, MD, discusses acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Sharman on Remaining Challenges With BTK Inhibitors in CLL

February 7th 2020

Jeff Sharman, MD, discusses the question of BTK inhibitors in treating patients with chronic lymphocytic leukemia.

Dr. Awan on the Role of Chemotherapy in CLL

February 5th 2020

Farrukh Awan, MD, discusses the role of chemotherapy in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Woyach on the Design of the Ongoing Alliance A041702 Trial in CLL

February 5th 2020

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the design of the ongoing phase III Alliance A041702 trial in chronic lymphocytic leukemia (CLL).

Dr. Davids on Exciting Data With Acalabrutinib in CLL

February 4th 2020

Matthew S. Davids, MD, MMSc, director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses exciting data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Novel Agents, Approaches Advancing CLL Paradigm

February 3rd 2020

Farrukh Awan, MD, discusses the introduction of acalabrutinib into chronic lymphocytic leukemia as well as other paradigm-shifting advances with BTK inhibitors, novel combinations, and emerging agents.

EU Panel Recommends Frontline Venetoclax/Obinutuzumab in CLL

January 31st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to the fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

2019 ASH; Best Abstracts for CLL

January 28th 2020

CAR T-Cell Therapy for Relapsed/Refractory CLL

January 28th 2020

Sequencing Strategies for CLL

January 28th 2020

PI3 Kinase Inhibitors for Relapsed/Refractory CLL

January 28th 2020

Management of CLL Progression After Ibrutinib

January 28th 2020

Resistance to Therapy in CLL

January 28th 2020

Combinations for Relapsed or Refractory CLL

January 28th 2020

Fixed-Duration Therapy for Relapsed CLL

January 28th 2020

Health Maintenance in CLL

January 28th 2020

Distinguishing Features Among BTK Inhibitors

January 28th 2020

Combining Targeted Therapies in CLL

January 28th 2020

Ibrutinib + Venetoclax for CLL

January 28th 2020